Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Vasculitis

Vasculitis

Subtypes of Vasculitis

ANCA-Associated Vasculitis 7 Kawasaki disease 6 Microscopic Polyangiitis 4 Eosinophilic granulomatosis with polyangiitis 3 Giant cell arteritis 1

20 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Vasculitis

6 trials tracked for Vasculitis: 2 in phase 3 or 4 and 1 with published results. The most-cited published study has 140 citations.

6Trials tracked
2Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 3 2 Phase 2 2 Other / NA 2
  1. Phase 3 Belimumab in Remission of VASculitis Completed · 140 cited
  2. Phase 3 Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis Completed
  3. Phase 2 A Study to Evaluate the Safety and Efficacy of CCX168 in Subjects With ANCA-Associated Vasculitis Completed
  4. Phase 2 Rituximab to Treat Hepatitis C-Associated Cryoglobulinemic Vasculitis Completed
  5. N/A Improving the Quality of Patient Care by Using a Clinical Expert System. Completed
  6. N/A PET-MRI in Diagnosing Patients With Cancer, Cardiac Diseases, or Neurologic Diseases Completed

Showing the 6 most-cited and recently-updated of 6 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Vasculitis: what the trials found

In patients with vasculitis, the use of rituximab in combination with cyclophosphamide was associated with a statistically significant achievement of disease remission compared to conventional therapy (p<0.001) 2.

While rituximab showed superior remission rates, there was no statistically significant difference between the rituximab and conventional therapy groups regarding the percentage of participants achieving a BVAS/WG score of 0 and successfully completing a glucocorticoid taper by 6 months post-randomization (p=0.133) 2.

Safety profiles were comparable between the rituximab and conventional therapy cohorts, with no statistically significant difference in the rate of selected adverse events (p=0.927) 2.

Recent results — preliminary, needs further review

  • A Phase 2 trial reported an 83% remission rate for patients treated with Rituximab, though this finding is not yet corroborated 4.

For the clinician treating this condition

  • Rituximab plus cyclophosphamide significantly improves disease remission rates compared to conventional therapy in vasculitis patients 2.
  • The addition of rituximab does not appear to significantly alter the rate of successful glucocorticoid tapering at 6 months compared to standard treatment 2.
  • Safety profiles for rituximab are comparable to conventional therapies regarding reported adverse events 2.

AI synthesis of 2 cited trials, updated Jun 26, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Expert review outlines diagnostic and therapeutic management strategies for eosinophilic granulomatosis with polyangiitis
Pediatrics Sys. Review
Expert review outlines diagnostic and therapeutic management strategies for eosinophilic granulomatosis with polyangiitis Rare Lung and Blood Disease Gets a Smarter Treatment Map
This expert review addresses the management of patients with eosinophilic granulomatosis with polyangiitis (EGPA), focusing on glucocorticoi…
A new expert roadmap shifts treatment for rare EGPA disease from steroids to targeted biologic drugs for patients with stubborn asthma and o…
Frontiers Apr 16, 2026
Surgical resection associated with spontaneous remission in Toxocariasis-linked vasculitis case
Allergy & Immunology Sys. Review
Surgical resection associated with spontaneous remission in Toxocariasis-linked vasculitis case A Common Parasite May Be Quietly Triggering Autoimmune Disease
A systematic review of a single case report describes a 45-year-old woman with Toxocariasis-associated small-vessel vasculitis.
A common roundworm infection may trigger serious autoimmune blood vessel inflammation, offering a potential cure for unexplained rashes and …
Frontiers Apr 16, 2026
ANCA-associated vasculitis associated with higher mortality and cardiovascular events in retrospective cohort analysis
Neurology Cohort
ANCA-associated vasculitis associated with higher mortality and cardiovascular events in retrospective cohort analysis New data links rare blood vessel diseases to higher death and heart risks
This retrospective cohort study analyzed 20,422 patients with granulomatosis with polyangiitis and 5,907 with microscopic polyangiitis using…
People with rare blood vessel diseases face nearly three times the death risk and higher heart attack rates compared to healthy people.
Frontiers Apr 16, 2026
Meta-analysis finds 7% incidence of suspected carotid atheromas on dental panoramic radiographs
Radiology & Imaging Meta-analysis
Meta-analysis finds 7% incidence of suspected carotid atheromas on dental panoramic radiographs Dental X-rays May Show Calcified Artery Plaque in Some Patients
This systematic review and meta-analysis of 34 cross-sectional studies in dental practice synthesizes evidence on calcified carotid artery a…
About 7% of dental X-rays show signs of artery plaque, meaning routine scans might reveal hidden heart risks that need medical attention.
Apr 15, 2026
Meta-analysis of DOACs versus conventional anticoagulation in Kawasaki disease with giant coronary artery aneurysms
Cardiology Meta-analysis
Meta-analysis of DOACs versus conventional anticoagulation in Kawasaki disease with giant coronary artery aneurysms Simpler Blood Thinners May Protect Kids' Damaged Heart Arteries
This systematic review and meta-analysis evaluated 594 children younger than 19 years with Kawasaki disease-associated giant coronary artery…
Children with the most serious heart complication of Kawasaki disease may soon swap daily shots for a once-a-day pill, with no drop in safet…
Frontiers Apr 13, 2026
Therapeutic plasma exchange in pediatric autoimmune diffuse alveolar hemorrhage shows 5 of 6 survival
Pediatrics Cohort
Therapeutic plasma exchange in pediatric autoimmune diffuse alveolar hemorrhage shows 5 of 6 survival Kids' Lungs Bleeding: Early Blood Swap Saves Lives
A retrospective cohort study of 6 pediatric patients with autoimmune diffuse alveolar hemorrhage requiring intensive care found that therape…
Early blood swaps saved six critically ill children with autoimmune lung bleeding, avoiding death in all cases treated with this urgent ther…
Frontiers Apr 12, 2026
Systematic review identifies shared immune mechanisms and therapeutic targets across cardiovascular inflammatory diseases
Rheumatology Sys. Review
Systematic review identifies shared immune mechanisms and therapeutic targets across cardiovascular inflammatory diseases Could one immune problem be driving three different heart conditions?
A systematic review examined shared immunological mechanisms across atherosclerosis, myocarditis, and vasculitis.
Three different heart diseases might share one immune trigger, suggesting new ways to treat plaque buildup, heart muscle inflammation, and b…
Frontiers Apr 8, 2026
Japanese AAV Cohort Shows MPA Has 67.6% Five-Year Survival; Glucocorticoid Reduction Not Linked to Better Outcomes
Infectious Disease Cohort
Japanese AAV Cohort Shows MPA Has 67.6% Five-Year Survival; Glucocorticoid Reduction Not Linked to Better Outcomes For Japanese patients with a rare autoimmune disease, survival remains challenging
A retrospective cohort study of 460 treatment-naïve Japanese patients with AAV found microscopic polyangiitis (MPA) had the poorest prognosi…
Japanese patients with microscopic polyangiitis face a five-year survival rate of 67.6%, as older age and kidney issues raise death risk.
Frontiers Apr 5, 2026